Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keytruda, Opdivo Set To Challenge Tecentriq In Bladder Cancer

Executive Summary

Phase III trial of Merck's Keytruda stops early with survival benefit as FDA accepts filing of Bristol's Opdivo, which has breakthrough therapy status and priority review.

Advertisement

Related Content

Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval
PD-1 Sponsors Expand Into Bladder, Head & Neck Cancer
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel